PR
Public post
Pharma Reg
Sep 2026 • linkedin
Post excerpt
🔬 UK Biosimilar Update: Lupin’s Ranibizumab — RANLUSPEC™ Receives UK Marketing Authorisations Lupin Healthcare (UK) Limited has received UK marketing authorisations for RANLUSPEC™ (ranibizumab) in two presentations: 💉 RANLUSPEC 10 mg/mL Solution for Injection 💉 RANLUSPEC 10 mg/mL Solution for Injection in Pre-Filled Syringe (PFS) Why this matters for the biosimilar market Ranibizumab is an established anti-VEGF biologic used in retinal diseases, and RANLUSPEC™ is Lupin’s biosimilar to the reference ranibizumab …
#PharmaReg#Biosimilars#Ranibizumab#RANLUSPEC#Lupin#LupinHealthcare
Find the people and context behind this post
Sign up for Super Carl to explore relationship context, warm paths, and relevant opportunities.